TENS of thousands of Brits are estimated to be unknowingly living with the silent heart condition that nearly killed ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Keith Gandal, professor of English in the Division of Humanities and the Arts at The City College of New York, and his ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

Year-to-date, Capricor Therapeutics has outperformed the broader market, boasting a YTD increase of 62.78%, compared to the S&P 500’s modest 19.88% rise. This performance underscores Capricor’s strong ...

Every month, Section Editor L.A. McKeown curates a roundup of recent news tidbits from journals and medical meetings around ...

Capricor Therapeutics (CAPR) stock gains as company plans to seek FDA approval for its lead candidate deramiocel (CAP-1002) ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on ...

Why are Natera and NeoGenomics battling in court over DNA technology? Discover how this legal fight could change the future ...